The CR rate was consistent across subgroups including men and women, patients with and without papillary disease, and ...

Event-free survival (EFS) in high-risk non-muscle invasive bladder cancer (NMIBC) improved significantly when patients ...

Johnson & Johnson (J&J) has reported more data supporting the efficacy of its intravesical drug release system TAR-200 in ...

May is Bladder Cancer Awareness Month and at Frontiers in Oncology, we are dedicated to spotlighting the groundbreaking discoveries transforming the ...

Mark Foundation Center for Lineage Plasticity team members Cory Abate-Shen, Anil Rustgi, and Michael Shen from Columbia ...

Award recipients Honored at the American Urological Association's 2025 Annual Meeting - - Fellowship designed to support the development of outstanding clinical cancer research investigators to ...

Among patients with non-muscle-invasive bladder cancer (NMIBC), neoadjuvant treatment with mitomycin C prior to transurethral ...

Aidixi plus BCG showed strong early efficacy and manageable safety in patients with high-risk, HER2-expressing ...

The targeted drug release device TAR-200 shows promising response and disease-free survival rates in specific populations of ...

The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent Imfinzi as adjuvant ...

M.D., Rutgers Cancer Institute of New Jersey: Dynamic intra-tumor heterogeneity in non-muscle invasive bladder cancer Taylor Goodstein, M.D., Emory University: Spatial Transcriptomic Profiling of ...